AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00779259
Drug: Theophylline 300mg
RxNorm normalized name: THEOPHYLLINE 300MG TAB
DrugBank: Theophylline (DB00277)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single doses of theophylline 300 mg as an immediate-release oral solution 80mg/15ml concentration administered alone at 7 am on Day 1 after an overnight fast of at least 10 hours and along with quinine sulfate (2 x 324 mg capsules) at 7am on Day 12 after an overnight fast of at least 10 hours.
Trial: NCT00779259
Drug: Theophylline 300 mg
RxNorm normalized name: theophylline 300 MG
DrugBank: Theophylline (DB00277)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single doses of theophylline 300 mg as an immediate-release oral solution 80mg/15ml concentration administered alone at 7 am on Day 1 after an overnight fast of at least 10 hours and along with quinine sulfate (2 x 324 mg capsules) at 7am on Day 12 after an overnight fast of at least 10 hours.
Trial: NCT00567255
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04678076
Drug: Ketoprofen Lysine
RxNorm normalized name: ketoprofen lysine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single oral dose of test product - ketoprofen 25 mg/5 ml oral gel stick pack - will be administered to healthy male and female volunteers under fed conditions in two consecutive study periods with a wash-out interval of at least 7 days between the two administrations.
Trial: NCT04678076
Drug: Ketoprofen Oral Product
RxNorm normalized name: ketoprofen Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single oral dose of reference product as a single dose of half of a bipartite sachet of OKi® 80 mg granules for oral solution will be administered to healthy male and female volunteers under fed conditions in two consecutive study periods with a wash-out interval of at least 7 days between the two administrations.
Trial: NCT02969473
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Radiotherapy: All patients underwent conventional radiotherapy, 1.8-2.0 Gy per fraction and 5 fractions per week. The prescribed dose was 60-64 Gy to PTV1 and 50 Gy to PTV2. Patients received either three-dimensional conformal radiotherapy (3D-CRT) or intensity-modulated radiation therapy (IMRT). 3D-CRT treatment plans were calculated by Pinnacle planning system and IMRT treatment plans were calculated by Monacle planning system. All patients were treated with a 6-MV or 8-MV linear accelerator.~Chemotherapy: All patients received two cycles of chemotherapy concurrently with radiotherapy. Patients assigned to the PF group received two cycles of PF regimen (cisplatin 80 mg/m2 delivered on day 1 and 5-FU 1000 mg/m2 continuous infusion over 24 hours daily on days 1-4) at a 3-week interval. In cases of grade 4 hematologic toxicity or severe non-hematologic toxicities, dose adjustment was performed in the subsequent chemotherapy cycle.
Trial: NCT04925531
Drug: Antibiotics
RxNorm normalized name: Antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: to examine if either the utility of antibiotics administered for 3 days or 5 days make a difference in the clinical outcomes after facial fractures in trauma patients.
Trial: NCT01565343
Drug: florbetapir F 18
RxNorm normalized name: Florbetapir F 18
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV injection, 370MBq (10mCi)
Trial: NCT02946931
Drug: Prizbind®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prizbind®
Trial: NCT02316743
Drug: Levothyroxine supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T4 supplementation for heart failure patients with subclinical hypothyroidism.
Trial: NCT01591902
Drug: Placebo-Control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.0 mL vials
Trial: NCT00892840
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Solution, Oral, 0 mg, Once daily, 14 days
Trial: NCT00213694
Drug: docetaxel and celecoxib
RxNorm normalized name: amlodipine and celecoxib
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00219895
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02086032
Drug: 1mg 17 beta-estradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparing sleeping quality between micronized progesterone and dydrogesterone users.
Trial: NCT01455909
Drug: ITCA 650 60 mcg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: exenatide in DUROS
Trial: NCT02058823
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The subjects receive 1 oral pill of placebo each morning during the second week of the two periods, so 14 pills in all.
Trial: NCT04635605
Drug: Control Test
RxNorm normalized name: CHEK-STIX URINALYSIS CONTROL TEST STRIP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arm B: Control Group. Placebo capsules 100 mg twice a day for 5 consecutive days, will be added to the current therapy of the patient, if any.
Trial: NCT02660008
Drug: ZP4207
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parallel trial in Group 1 and cross-over trial in Groups 2-4 with single doses of ZP4207 administered s.c. to hypoglycemic Type 1 diabetic patients
Trial: NCT03856268
Drug: 'Drug-Induced Menopause' Group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Women undergoing gonadal suppression via leuprolide acetate (Lupron \[AbbVie Inc.\]) will be enrolled at the University of Colorado-Denver.
Trial: NCT01607203
Drug: Decapeptyl Daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Decapeptyl 0.2 mg SC once 1day
Trial: NCT01629199
Drug: placebo of rhEGF(recombinant human Epidermal Growth Factor)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00568633
Drug: Best standard care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention consist of:~* Consolidation chemotherapy (3-4 cycles of cytarabine +/- an anthracycline agent, or other consolidation)~* Autologous transplantation~* Non-Myeloablative unrelated-donor transplant, +/- TLI and ATG conditioning~* Umbilical cord blood transplantation~* Haploidentical transplantation
Trial: NCT05043324
Drug: AntiCov-220 (1)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The daily maintenance, AntiCov-220 (1) dose is to take 3 times a day, 1 tablet each time.
Trial: NCT05043324
Drug: AntiCov-220 (2)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The daily maintenance, AntiCov-220 (2) dose is to take 3 times a day, 1 tablet each time.
Trial: NCT00566202
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Form= capsule, route= oral use. Administration once daily for 8 weeks.
Trial: NCT00305929
Drug: Treatment with Tookad VTP
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00305929
Drug: Treatment with Tookad VTP
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tookad 2 mg/kg
Trial: NCT00305929
Drug: Treatment with Tookad VTP
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg/kg
Trial: NCT00068770
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Celecoxib will begin 1 week prior to RT at 400mg bid orally. One day 1 only 1 dose will be administered. Starting on day 2 and throughout treatment until progression, 2 doses will be administered at least 12 hours apart. Celecoxib will continue throughout the 6 week course of RT.
Trial: NCT01948856
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration - During 6 months : 1 sachet per day in the morning on an empty stomach~* First month: 4 consecutive days per week during 3 consecutive weeks~* 5 next months: 4 consecutive days per month at monthly intervals
Trial: NCT04458324
Drug: Buspirone placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects take a placebo tablet twice a day for 6 months.
Trial: NCT02660138
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AbobotulinumtoxinA Placebo 600 U intra detrusor injection in two treatment periods (Initial and Retreatment phase) delivered at 30 injection points
Trial: NCT02660138
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AbobotulinumtoxinA Placebo 800 U intra detrusor injection in two treatment periods (Initial and Retreatment phase) delivered at 30 injection points
Trial: NCT03618589
Drug: Opioid
RxNorm normalized name: OPIOIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in the opioid group received the only opioid (5mg of oxycodone three times a day) for 8 weeks.
Trial: NCT02564952
Drug: GWP42003-P
RxNorm normalized name: P
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GWP42003-P was presented as an oral solution containing 100 mg/milliliter (mL) cannabidiol (CBD) in the excipients sesame oil and anhydrous ethanol (79 mg/mL) with added sweetener (0.5 mg/mL sucralose) and strawberry flavoring (0.2 mg/mL). Participants received up to a maximum of 30 mg/kg/day.
Trial: NCT00993629
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: adjunctive placebo
Trial: NCT04268823
Drug: QBW251
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule 300mg
Trial: NCT04268823
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule 300mg
Trial: NCT04276727
Drug: MINT study IMP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Application of gel for 6 weeks.
Trial: NCT02379650
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01527942
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous Acetaminophen 1,000 mg IV
Trial: NCT01527942
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo - IV administration 0.9% 100 ml Sodium Chloride (NaCl)
Trial: NCT00580931
Drug: Nicotinamide
RxNorm normalized name: Nicotinamide
DrugBank: Nicotinamide (DB02701)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1500 mg twice a day for 6 months
Trial: NCT00580931
Drug: Enduramide placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tab twice a day
Trial: NCT00043550
Drug: Pill Placebo
RxNorm normalized name: placebo Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive a pill placebo.
Trial: NCT03125239
Drug: LY2874455
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This will be followed by cycles of combination therapy with merestinib and LY2874455. Each of these cycles are 28 days long. • LY2874455 will be taken by mouth twice a day. You may take LY2874455 twice daily for 14 days, 21 days, or 28 days each cycle depending on the dose level you are assigned.
Trial: NCT00137540
Drug: anti-arrhythmic drug therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03054168
Drug: Sustanon 250
RxNorm normalized name: SUSTAGEN PWDR CHOCOLATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The frequency of the injection will be every 2 weeks, 250mg of testosterone, intramuscular injection.
Trial: NCT01917656
Drug: sulphonylurea
RxNorm normalized name: metformin and sulfonylureas
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will continue on their pre-trial SU tablet treatment, doses unchanged
Trial: NCT00322972
Drug: Mass treatment with oral azithromycin to an entire community
RxNorm normalized name: Aldex AN
DrugBank: Doxylamine (DB00366)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: For baseline and follow-up surveys prior to azithromycin distribution, a stratified random sample from two age groups will be chosen: 1) 60 study participants younger than 10 years old and 2) 60 study participants aged 10 years and above. Clinical examination will be performed and conjunctival swabs will be taken from all the study participants. For study arm C and D, nasopharyngeal swabs will be collected from 10 randomly selected children among the 60 participants under 10 who were recruited for conjunctival swabbing. Then a single dose of azithromycin will be distributed according to study design: in tablet form for adults; a weight-adjusted tablet dose for children ages 8-10; and pediatric suspension for children ages 1 - 7.
Trial: NCT03717272
Drug: AEF0117
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AEF0117 capsules
Trial: NCT03717272
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corn oil capsule manufactured to mimic AEF0117 capsule
Trial: NCT02970682
Drug: SFX-01
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stabilised Sulforaphane
Trial: NCT02970682
Drug: Aromatase Inhibitors
RxNorm normalized name: Aromatase inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02687867
Drug: Vitamin K antagonist
RxNorm normalized name: Vitamin K antagonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: As prescribed by treating physicians
Trial: NCT00254579
Drug: CP-675,206
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg/kg Q12W dosing regimen
Trial: NCT02251431
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cohort A only
Trial: NCT01042379
Drug: Standard Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paclitaxel: 80 mg/m2 IV during the 12 weekly treatment cycles post randomization; Doxorubicin: 60 mg/m2 IV after completion of the 12 weekly treatment cycles and prior to surgery for weeks 13-16; Cyclophosphamide: 600 mg/m2 IV after completion of the 12 weekly treatment cycles and prior to surgery for weeks 13-16
Trial: NCT01042379
Drug: PLX3397
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arm is closed.
Trial: NCT00917293
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 2 pills, po bid.
Trial: NCT03317301
Drug: HL151
RxNorm normalized name: Hydroxylapatite
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 times a day(Day, Night), 2 weeks of treatment / Day: HL151 (1Tab)+Talion Tab (Placebo)(1Tab), Night: HL151 (Placebo)(1Tab)+Talion Tab (Placebo)(1Tab)
Trial: NCT03317301
Drug: Talion Tab
RxNorm normalized name: BENZOCAINE 5 g in 100 mL TOPICAL CREAM [Stallion]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 times a day(Day, Night), 2 weeks of treatment / Day: HL151 (Placebo)(1Tab)+Talion Tab (1Tab), Night: HL151 (Placebo)(1Tab)+Talion Tab (1Tab)
Trial: NCT01042379
Drug: ARX788
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ARX788, 1.5 mg/kg Q3W, IV for 12 weeks
Trial: NCT02864901
Drug: Chewing Gum Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02630901
Drug: PRX003
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00745459
Drug: NPO-11
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mL NPO-11
Trial: NCT00739206
Drug: SAR97276A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose based on body weight
Trial: NCT03187899
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-10cc of Normal Saline will be given to patients receiving a traditional interscalene block and a sham superficial plexus block.
Trial: NCT06103656
Drug: Drug: Chinese Herbal Medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules, 26 month course, starting 2 months pre-OIT.
Trial: NCT06103656
Drug: Drug: Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules that look identical to E-B-FAHF-2 containing corn starch, 26 month course, starting 2 months pre-OIT
Trial: NCT02622906
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicule injection per month during 6 months
Trial: NCT02116335
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stress response and vascular function will be assessed 3 days following twice per day placebo
Trial: NCT01836094
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral, one time
Trial: NCT04434378
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo will be given to a randomized group of patients
Trial: NCT00718562
Drug: AMN107
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04008797
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxorubicin dosing.
Trial: NCT00896038
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-active placebo
Trial: NCT00946556
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo po od for 2 months
Trial: NCT00185107
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01876628
Drug: Clindamycin
RxNorm normalized name: Clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clindamycin dose 300mg four times each day for 2 days, within 48 hours of commencing flucloxacillin. Clindamycin is over-encapsulated and externally identical to placebo.
Trial: NCT01876628
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo is externally identical to the over-encapsulated clindamycin and is taken four times each day for 2 days
Trial: NCT02439359
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01954927
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be prepared by the SJCRH pharmacy and will be similar in appearance, quantity and taste to the gabapentin drug. Patients randomized to the placebo arm will receive a single dose of placebo as soon after enrollment as feasible. The placebo dose will be given orally and will be approximately 15 mg/kg with a maximum dose of 900mg.
Trial: NCT00003388
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00003388
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00003388
Drug: pegylated liposomal doxorubicin hydrochloride
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02848729
Drug: Oral Acetaminophen
RxNorm normalized name: acetaminophen Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen for oral administration (2 tablets, 500 mg/tablet)
Trial: NCT02848729
Drug: IV Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen for intravenous (IV) administration (1,000 mg/100 mL)
Trial: NCT02848729
Drug: Placebo Tablets
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets matching oral acetaminophen
Trial: NCT00361413
Drug: control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: these patients will receive the same treatment as group A, without alefacept
Trial: NCT00018174
Drug: Fluoxetine
RxNorm normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00018174
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00693862
Drug: levodopa, carbidopa, entacapone
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00693862
Drug: levodopa, carbidopa
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00998218
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranolazine at 1000 mg BID (or 500 mg BID if the 1000 mg dose was not tolerated) or a comparable placebo for the next 4 weeks
Trial: NCT00242567
Drug: Zoledronic Acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zoledronic acid was provided by Novartis in vials containing 4 mg/5 mL liquid concentrate. Prior to administration, the liquid concentrate from one vial was to be further diluted with 100 mL of calcium-free infusion solution (0.9 % weight by volume sodium chloride solution or 5 % weight by volume glucose solution). If refrigerated, the solution had to be allowed to reach room temperature before administration.~After addition of the liquid concentrate to the infusion media, the infusion solution was to be used as soon as practicable to reduce the risk of microbiological hazard. If storage of the solution was necessary, it had to be refrigerated at temperatures between 2-8 degrees C and was to be used within 24 hours.~The infusion solution containing 4 mg zoledronic acid was to be administered every 4 weeks as an i.v. infusion over no less than 15 minutes.
Trial: NCT01277107
Drug: Placebo capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Identical placebo capsule
Trial: NCT00308100
Drug: Hydroxyethylstarch 130/0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HES 130/0.4, administered intra- and perioperatively, max. daily dose: 33ml/kg BW; if needed, additionally albumin is administered (ratio crystalloid to colloid= 1:1)
Trial: NCT00308100
Drug: 5% Albumin
RxNorm normalized name: Flexbumin 5% Albumin (Human) Solution for Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% albumin, administered intra- and perioperatively
Trial: NCT04311411
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC.
Trial: NCT02305329
Drug: BIA 9-1067
RxNorm normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01650012
Drug: eplerenone
RxNorm normalized name: Eplerenone
DrugBank: Eplerenone (DB00700)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: target 50 mg per day titrated down for hyperkalemia or hypotension
Trial: NCT01650012
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01975324
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo (sugar pill) twice a day for two weeks